Delta-Fly Pharma is a Japanese oncology-focused drug discovery company that develops novel anticancer agents using its proprietary 'Module Drug Discovery' platform, which assembles existing anticancer active substances with innovative modifications to improve the clinical balance of efficacy and safety. The company's lead pipeline candidate, DFP-10917, is a low-dose continuous infusion nucleoside analogue currently in Phase 3 clinical trials in the U.S. for relapsed/refractory acute myeloid leukemia (AML), with additional combination studies with venetoclax ongoing. Other pipeline assets include DFP-14323 (oral immunomodulator in Phase 3 in Japan), DFP-11207, DFP-14927, DFP-17729, and DFP-10825, targeting a range of solid and hematologic malignancies.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Delta-Fly Pharma is a Japanese oncology-focused drug discovery company that develops novel anticancer agents using its proprietary 'Module Drug Discovery' platform, which assembles existing anticancer active substances with innovative modifications to improve the clinical balance of efficacy and safety. The company's lead pipeline candidate, DFP-10917, is a low-dose continuous infusion nucleoside analogue currently in Phase 3 clinical trials in the U.S. for relapsed/refractory acute myeloid leukemia (AML), with additional combination studies with venetoclax ongoing. Other pipeline assets include DFP-14323 (oral immunomodulator in Phase 3 in Japan), DFP-11207, DFP-14927, DFP-17729, and DFP-10825, targeting a range of solid and hematologic malignancies.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →